This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kondo, S. Articles by Takeuchi, J. Search for Related Content PubMed PubMed Citation Articles by Kondo, S. Articles by Takeuchi, J.

Transfection with a bcl-2 Expression Vector Protects Transplanted Bone Marrow from Chemotherapy-induced Myelosuppression¹

Department of Neurosurgery, National Utano Hospital [S. K., D. Y., T. M., J. T.], Kyoto 616, and Department of Neurosurgery, Faculty of Medicine, Kyoto University [Y. O., H. K.], Kyoto 606, Japan

The use of cytokines such as granulocyte-colony-stimulating factor (G-CSF) to ameliorate chemotherapy-induced myelosuppression may not only stimulate the recovery of normal hematopoietic cells but may also enhance the proliferation of the tumor cells with functional receptors for these cytokines. In this study, we show that administration of recombinant human (rh) G-CSF decreased the in vitro and in vivo cytotoxic effects of Adriamycin or etoposide on L1210 murine leukemic cells with receptors for rhG-CSF. Transplantation of bone marrow cells expressing high levels of bcl-2 from a retroviral construct [MPZenNeo(bcl-2)] (bcl-2-BMT) did not decrease the in vivo cytotoxic effect of etoposide on L1210 cells, but enabled recovery of myelopoiesis following etoposide-induced myelosuppression to almost the same extent as did the administration of rhG-CSF. These findings suggest the possibility that bcl-2 transfection could be used to protect transplanted bone marrow from chemotherapy-induced myelosuppression on behalf of administration of rhG-CSF, in case of treatment of tumors with functional receptors for rhG-CSF.

¹ This work was supported in part by the Grant-in Aid for Cancer Research [5–6] from the Ministry of Health and Welfare of Japan and in part by a Grant from Japan-China Medical Association.

² To whom requests for reprints should be addressed, at Department of Neurosurgery, National Utano Hospital, 8-Ondoyama-cho, Narutaki, Ukyo-ku, Kyoto 616, Japan.

Received 10/18/93. Accepted 3/29/94.

This article has been cited by other articles:

				A. Villunger, L. A. O'Reilly, N. Holler, J. Adams, and A. Strasser Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and p38 Mitogen-activated Protein Kinase: Regulators of Distinct Cell Death and Survival Pathways in Granulocytes J. Exp. Med., August 28, 2000; 192(5): 647 - 658. [Abstract] [Full Text] [PDF]

				A. Rebbaa, P. M. Chou, I. Vucic, B. L. Mirkin, T. Tomita, and E. G. Bremer Expression of Bisecting GlcNAc in Pediatric Brain Tumors and Its Association with Tumor Cell Response to Vinblastine Clin. Cancer Res., November 1, 1999; 5(11): 3661 - 3668. [Abstract] [Full Text] [PDF]

				S. Kondo, Y. Tanaka, Y. Kondo, M. Hitomi, G. H. Barnett, Y. Ishizaka, J. Liu, T. Haqqi, A. Nishiyama, B. Villeponteau, et al. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation FASEB J, July 1, 1998; 12(10): 801 - 811. [Abstract] [Full Text]